Cala Health develops wearable neuromodulation devices designed to reduce hand tremor in people with essential tremor. The company’s technology is delivered through a wrist-worn device that targets peripheral nerves involved in motor control. Its platform is based on transcutaneous afferent patterned stimulation (TAPS), a non-invasive approach intended for repeated, at-home use. Cala Health positions its solution within regulated clinical care rather than consumer wellness.

The technology delivers patterned electrical stimulation to the median and radial nerves at the wrist, which are involved in tremor-related neural circuits. Stimulation parameters are personalized to the individual user to optimize therapeutic effect. By modulating afferent nerve signals, the system aims to influence central tremor pathways without direct brain stimulation. The device is designed for ease of use, enabling patients to administer therapy independently.

Cala Health targets individuals diagnosed with essential tremor who require non-pharmacological treatment options. The device is prescribed and used within established medical frameworks, complementing or providing alternatives to medication and invasive procedures. Its focus on wearable, patient-specific neuromodulation reflects broader efforts to make neurological therapies more accessible and personalized.